Abstract
At present no Laboratory test is available to predict the evolution of J H (Graves'disease). A follow ip to 2 to 14 y. was carried up in 59 patients aged 2 4/12 to 17 y. old (X ± SD: 9.4 ± 3.9). They all received antithyroid drugs as initial treatment. Thirty six patients followed for 3 to 14 y., could be reevaluated with T4, T3 and TSH and/or TRH after treatment in at least 2 ocassions: at short-term (ST: 1-2 y. post onset of treatment) and at long-term (LT:more than 3 y.; X ± 6.23 ± 3.3). Twenty three patients (64%) remained hyperthyroid (Hper) between ST and LT and 9(25%) hypo or euthyroid (Hpo/Eu) between ST and LT; only 4 (11%) changed from Hper at ST to Hpo/Eu at LT. Thus, 89% did not modify their thyroid function between ST and LT. The period of the evolution from Hper to Hpo/Eu showed two distinct populations, one with a X ± SD of 17.3 ± 3.8 months and another with X ± SD of 9.4 ± 2.5 y. It is concluded that evaluation of thyroid function at ST is useful to predict their status at LT since 90% of patients showed no variations. Since patients who changed thyroid fuction from Hper to Hpo/Eu at ST did it in X 17.3 months it is advisable to wait up to this time to select another therapeutic options. If Hper persists the possibility of I 131 administration should be considered to avoid the excessively long treatment required by the unrelenting course of this disease.
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Iorcansky, S., Gruñelro de papendieck, L., Belgorosky, A. et al. 23. JUVENILE HYPERTHYROIDISM (J H): THERAPEUTIC OPTIONS ACCORDING TO THE PREDICTION OF THE EVOLUTION. Pediatr Res 23, 651 (1988). https://doi.org/10.1203/00006450-198806000-00046
Issue date:
DOI: https://doi.org/10.1203/00006450-198806000-00046
